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At a Glance Commentary 
Scientific knowledge on the subject
Antibiotic resistance challenges current practice. New antimicrobials approved for clinical 
application are scarce, and this underscores the urgent need for alternative strategies. 
Phage therapy is a promising approach for the treatment of antibiotic resistant bacteria, 
however infection specific, proof-of-concept experimental studies are currently missing. 
What this study adds to the field
We assessed the efficacy of phage therapy for the treatment of experimental ventilator 
associated pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in 
rats. Phage treatment improved survival compared to placebo and was equally as effective 
as traditional antibiotics in controlling MRSA infection. Combination of phages with antibiotics 
did not further improve outcome in this experimental setting.
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Abstract:
Rationale: Infections caused by multidrug resistant bacteria are a major clinical challenge. 
Phage therapy is a promising alternative antibacterial strategy. 
Objective: To evaluate the efficacy of intravenous phage therapy for the treatment of ventilator 
associated pneumonia due to methicillin-resistant Staphylococcus aureus in rats.
Methods: A randomized blinded controlled experimental study compared intravenous 
teicoplanin (3mg/kg, n=12), a cocktail of four phages (2-3 x 109 plaque forming units/ml of 
2003, 2002, 3A and K, n=12) and combination of both (n=11), given two, 12 and 24 hours after 
induction of pneumonia, then once daily for four days. The primary outcome was survival at 
day four. Secondary outcomes were bacterial and phage densities in lungs and spleen, 
histopathological scoring of infection within the lungs and inflammatory biomarkers in blood.
Measurements and Main Results: Treatment with either phages or teicoplanin increased 
survival from 0% to 58% and 50% respectively (p<0.005). Combination of phage with 
antibiotics did not further improve outcome (45% survival). Animal survival correlated with 
reduced bacterial burden in the lung (1.2 x 106 CFU/g of tissue for survivors versus 1.2 x 109 
CFU/g for non-surviving animals, p<0.0001), as well as improved histopathological outcomes. 
Phage multiplication within the lung occurred during treatment. IL-1β increased for all treatment 
groups over the course of therapy.
Conclusions: Phage therapy was as effective as teicoplanin in improving survival and 
decreasing bacterial load within the lungs of rats infected with methicillin-resistant S. aureus. 
Combining antibiotics with phage therapy did not further improve outcomes.
Key Words: bacteriophage; antibiotic resistance, microbial; pneumonia, ventilator associated.
Abstract word count without key words: 244 
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INTRODUCTION
Ventilator associated pneumonia (VAP) is common in mechanically ventilated patients (1-3). 
The rapid development of antibiotic resistance in this infection setting both challenges 
treatment efficacy and is associated with increased morbidity and mortality (4-6). 
Staphylococcus aureus is consistently being reported as one of the top three pathogens 
isolated in this particular setting (7, 8). Although the rate of methicillin-resistance is decreasing 
worldwide, methicillin-resistant S. aureus (MRSA) still accounts for a significant portion of total 
VAP cases (5-15%) (2, 7, 9); this proportion varies across continents and even across hospitals 
within the same country (2, 9, 10).
The use of bacterial viruses (bacteriophages or phages) as antimicrobials is being actively re-
evaluated as an alternative/complementary strategy to antibiotics, mainly in response to the 
rise in multidrug resistant infections (11, 12). The lack of trials conducted according to 
standards of good practices explains why phages are not yet part of the western 
pharmacopeia. Hence, studies ranging from experimental proof-of-concept to randomized 
controlled clinical trials are necessary to evaluate the potential of phage therapy for the 
treatment of multidrug resistant infections. The first phase I/II multicenter randomized 
controlled study (PhagoBurn) evaluating GMP-phage preparations has recently been 
published (13). PhagoBurn evaluated phage therapy for the treatment of burn wound infections 
due to Pseudomonas aeruginosa and while phages were well tolerated, their efficacy was 
challenged by innate bacterial immunity to phages and low phage titres within the study 
treatment cocktails (14, 15).
To date, many questions are yet to be investigated pertaining to phage therapy, especially in 
the context of pneumonia. For example, no clinical trial has evaluated phage therapy for the 
treatment of pneumonia. Additionally, there is a lack of preclinical data addressing (i) phage 
pharmacokinetics in the lung infection environment, (ii) frequency and mechanism of phage 
resistance selection in vivo, (iii) the effectiveness and appropriateness of phage-antibiotic 
combinations and (iv) the use of clinically validated administrative routes.  
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Accordingly, the goal of the present work was to evaluate the efficacy of phage therapy alone 
and in combination with teicoplanin for the treatment of experimental VAP due to methicillin-
resistant S. aureus (MRSA) in an experimental rat model. Emergence of phage resistance was 
monitored and data documenting phage pharmacokinetics in infected and non-infected 
animals were collected.
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MATERIAL AND METHODS
The ventilator-associated pneumonia model. Male Wistar rats (Crl:WI(Han), Charles River, 
Germany), aged 9-10 weeks (280 – 330g) were housed in specific pathogen-free rooms (12h 
light/dark conditions, 23°C ± 1°, water and nutrition ad libitum). Animal protocols were run in 
accordance with the guidelines of the Swiss Animal Protection Law and were approved by the 
Cantonal Committee on Animal Experiments of the State of Bern (approval BE 83/17).
The VAP model published by Wu et al. (16) was adapted as follows (Fig. 1A). Animals were 
anaesthetized with sevoflurane followed by intraperitoneal injection of 20 µg/kg fentanyl. The 
anaesthetized animals were intubated with a G14 angiocath (Braun, Vasofix) (t-4). Correct 
placement of the endotracheal tube was confirmed using capnometry. A polyurethane catheter 
(PU-065-50, SAI Infusion Technologies) was inserted in the jugular vein and connected to a 
harness with a Luer valve (QuickConnect, SAI Infusion Technologies) for therapeutic 
interventions and blood samplings. Rats were ventilated for four hours (10 mL/kg tidal volume, 
5 cmH2O of positive end-expiratory pressure, 50 breaths/min with FiO2 0.35) on ventilators for 
small animals (VentElite, Harvard Apparatus). After ventilation, animals were infected by 
instillation of 0.15 mL inoculum containing 6-8 x 109 colony forming units (CFU, LD100) of 
stationary phase S. aureus strain AW7 (17) (See online data supplement) into the endotracheal 
tube (t0). Strain AW7 is a clinical MRSA strain producing α-hemolysin, a critical mediator of S. 
aureus pneumonia (18, 19). Immediately after inoculation, animals were extubated and placed 
into separate cages.
Treatment protocol. Two hours (t2) after bacterial challenge, animals were randomly divided 
into four groups (n=10-12) and received: (i) 0.3ml of 0.9%NaCl (control); (ii) an intravenous 
phage cocktail consisting of equal titers (~2-3 x 109 PFU/ml) of phages 2003, 2002, 3A and K; 
(iii) intravenous teicoplanin (3mg/kg); (iv) a combination of both. Each treatment was further 
applied at t12, t24, t48 and t72 (Fig. 1A). We choose a glycopeptide antibiotic as the control 
treatment, as it is the standard of care according to current guidelines (3, 20). We preferred 
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teicoplanin to vancomycin, because besides being equivalent to vancomycin (21, 22), its 
pharmacokinetic profile better matched our phage treatment regimen.
The respective therapies were given blinded (see online data supplement). Seven animals 
instilled with 0.15ml NaCl 0,9% after ventilation (t0) served as the SHAM group and seven 
uninfected animals were administered phages (t2, t12, t24, t48 and t72) for pharmacokinetic 
studies (SHAM+phage).
Blood sampling was performed at catheter insertion (t0), at the start of therapy (t2), t24 and t96. 
In non-surviving animals, blood was collected from animals immediately after death or 
euthanasia (see online data supplement), dissections were performed and lungs and spleens 
were collected. Surviving animals were euthanized at t96 with pentobarbital (150 mg/kg) before 
dissection.
Outcomes. Survival at t96 was the primary outcome. The secondary outcomes were 1) 
bacterial and phage loads in the lungs and spleen; 2) histopathological scoring of pneumonia 
(23); 3) quantification of inflammation biomarkers in the blood and 4) assessment of phage 
resistance. Methods describing secondary outcomes can be in the online data supplement.
Statistics. Log-rank tests were used to assess survival. Animals were divided into two 
mortality groups, Survivors and Non-survivors. Differences between the groups were 
determined using t test, Mann Whitney test, ordinary one- or two-way ANOVA. Corrections for 
multiple pairwise comparisons were achieved using the methods of Tukey (one-way) or Holm-
Sidak (two-way). Analyses were performed using GraphPad Prism (v7) with a significance 
level of p<0.05.
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RESULTS
Phage therapy significantly improves survival in rats with experimental VAP.
The experimental model of VAP was rapidly lethal, with 80% of untreated animals succumbing 
to infection within 12 hours and 100% mortality by 86 hours (Fig. 1B). To assess the efficacy 
of phage therapy in this infection setting, we developed a treatment cocktail consisting of four 
phages with complimentary host-range profiles, which infected 91.6% of S. aureus isolates 
tested (Fig. E1A, online data supplement). Importantly, the combination of multiple phages 
was shown to limit the development of phage resistance in vitro (Fig. E1B, online data 
supplement). Application of the cocktail improved survival compared to placebo (p< 0.001, log-
rank test). All animals treated with phages survived for at least 12 hours following infection and 
58% of the animals survived until the end of the experiment. This was comparable to the effect 
of the standard of care treatment teicoplanin (50% survival, p=0.85). 
The combination of phages and antibiotic did not further improve outcome compared to phage 
or antibiotic alone (45% survival, p=0.57 and 0.74, respectively. Fig 1B). In support of this, we 
did not observe synergy or antagonism for teicoplanin and the phage cocktail in vitro (Fig. E2, 
online data supplement).
Phage therapy controls bacterial load within infected lungs of surviving rats. 
Mortality correlated with high bacterial load within the lung (Fig. 2A). Animals that succumbed 
to infection had 1,000-times more MRSA in the lung when compared to those that survived 
(1.2 x 109 CFU/g verses 1.2 x 106 CFU/g, respectively, p <0.0001, t test). When compared with 
teicoplanin, phages were equally as effective at controlling bacterial loads within the lung of 
infected rats, and combination of phages and antibiotic did not further reduce lung bacterial 
burden (Fig. 2B, no difference between treatment groups, p=0.72, two-way ANOVA). 
Metastasis to the spleen was infrequently detected (13 of 42 spleens tested) and there was no 
difference in spleen bacterial loads between groups based on time-to-mortality (Fig. 2C, p = 
0.30, Mann Whitney test). 
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In the absence of pneumonia, intravenous application of phages did not lead to phage 
accumulation within the lung. However, phages were detected in the lungs of rats with 
pneumonia treated with the phage cocktail, suggesting either amplification and/or persistence 
of phages at the site of infection (Fig. 2D). The average phage load for the lung was higher in 
non-surviving animals, however this was not statistically significant (Fig. 2E, p=0.30, Mann 
Whitney test). Similarly, a positive correlation between CFU/g of lung and PFU/g of lung was 
observed, but this did not reach statistical significance (Fig 2F, r = 0.33, p = 0.12, Pearson two-
tailed correlation test). In the absence of infection, phages were sequestered by the spleen 
(Fig. 2D).
Despite bacterial load reductions within the lungs, phage treatment did not eradicate the 
infection (Fig. 2B). To evaluate selection of phage resistance, which may explain MRSA 
persistence, we performed phage cross-streaking assays using a total of 100 bacterial isolates 
taken from 10 infected lungs of animals treated with phages, and 10 infected lungs from 
animals treated with a combination of phages and antibiotics. All of the MRSA strains tested 
remained susceptible to phage lysis irrespective of rat mortality, suggesting that persistence 
was not due to the evolution of resistance (Fig. 3).
Phage and/or antibiotic therapy is associated with reduced lung damage in surviving 
rats. 
Experimental MRSA VAP resulted in considerable lung damage (Fig. 4A). The lungs of 
ventilated but uninfected rats received a histopathological score of “1” indicating mild injury 
with mild to moderate perivascular and peribronchiolar inflammation and oedema. Application 
of phages in uninfected rats did not result in additional lung damage. All infected rats that 
succumbed to infection early had an average total histopathological score of 2.65 indicating 
moderate to severe disease (Fig. 4B). In contrast, survival was associated with a lower 
histopathological score compared to rats that did not survive (average of 2.06, p> 0.0001, 
representative image Fig. 4C). The score for surviving animals was still higher than that of 
uninfected rats (p= 0.056). More specifically, surviving rats treated with either phages, or 
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teicoplanin displayed a reduction in lung damage compared to treated rats that did not survive 
(Fig. 4D, p< 0.05 for both, Holm-Sidak test). The difference between histopathological score 
for survivors and non-survivors treated with a combination of phages and teicoplanin however 
was not significant (Fig. 4D, p= 0.32). Given the importance of staphylococcal exotoxins in this 
infection setting, we also analyzed necrosis independent of other histopathological factors. 
MRSA induced significant necrosis when compared to uninfected SHAM controls. For infected 
animals, high scores for necrosis correlated with poor animal survival (Fig. E3A) and there 
were no differences in necrosis scores between each treatment group (Fig. E3B). To 
characterise this further, we performed rabbit red blood cell (RBC) lysis assays for filtered 
supernatants from phage-exposed cultures as a functional measure of exotoxin production. In 
support of the necrosis data (Fig. E3B), phages had no discernible impact on RBC cell lysis in 
vitro (Fig. E4).   
Lung inflammation correlated with increased cytokines in blood. 
The cytokine profile in blood of MRSA infected rats was different to that of uninfected controls 
(p< 0.01, two-way ANOVA, Fig. 5A). MRSA infection resulted in an increase in two of the six 
pro-inflammatory cytokines tested. IL-6 was increased in MRSA infected rats compared to 
SHAM controls (p< 0.01), and whilst TNFα levels were below the limit of detection in uninfected 
rats, levels were elevated for 22 of the 25 MRSA infected rats. IL-1β levels increased 
significantly in each treatment group over the course of therapy including uninfected animals 
treated with phages (SHAM+phage), which suggests that the IL-1β response is induced by the 
phage in the absence of bacterial infection (Fig. 5B). IL-18, an additional inflammasome marker 
was not detectable in samples after 96 hours of treatment (data not shown). IL-1α increased 
only in MRSA infected animals treated with phages (with or without antibiotic). The levels of 
TNFα and IL-6 returned to baseline levels following 96 hours of treatment (Fig. 5B). IL-10, and 
IL-17A levels did not vary over the course of treatment (data not shown). 
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DISCUSSION
Phage therapy is a promising alternative and/or complementary strategy to overcome the rising 
problem of multi-resistant bacteria. Although an increasing amount of data has been generated 
in the last five years, strong pre-clinical evidence and milestone clinical studies are still lacking 
to support its use in human medicine (24, 25). We recently reported a positive effect of a 
cocktail of bacteriophages for the treatment of P. aeruginosa experimental endocarditis (26) 
as part of the Phagoburn clinical trial (13); in the current report, we systematically evaluated 
the efficacy of a new anti-S. aureus phage cocktail for the treatment of VAP in rats.
To better mimic the clinical setting, we adapted a model of VAP previously described by Wu 
et al. by using higher oxygen fraction (0.35 vs 0.21) and by lowering minute-ventilation rates. 
This first enabled us to generate the typical ventilator-induced injuries observed in ICU patients 
as demonstrated by the mild to moderate, perivascular and peribronchiolar inflammation 
reported in ventilated but not infected animals and secondly, these adaptations increased the 
severity of the experimental model, with infected but untreated animals harbouring high 
bacterial loads within the lungs (Fig. 2A). 
Our study has some important implications. First, we could demonstrate that phage therapy 
significantly reduced mortality compared to placebo in a lethal model of staphylococcal 
pneumonia (Fig. 1B). This effect was comparable to that of the standard of care. Similar results 
have been reported in other pneumonia models caused by gram-negative pathogens including 
Klebsiella pneumoniae, Acinetobacter baumannii and P. aeruginosa (14, 15, 27, 28). 
Nevertheless, our report, focusing on a troublesome clinically relevant antibiotic-resistant 
gram-positive pathogen, better emulates the clinical setting, in the way that we first ventilated 
the animals, before infecting them via the endotracheal tube – mimicking bronchoaspiration – 
and then treating them with phages given intravenously as opposed to via intraperitoneal 
injection.
Phages were detected in infected lungs and were not detected in the absence of infection (Fig. 
2B) highlighting the capacity for phages administered in the bloodstream to become 
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concentrated at the site of infection. Additionally, we observed sequestration of phages in the 
spleen of uninfected animals, as has been described in other experimental models (29-31), 
the physiological significance of which remains to be determined. Phage titers did not explain 
early death (ie. one might expect that low titers early on may lead to poor outcomes), however 
this result is confounded by lower bacteria (hosts for phage replication) in the lungs of surviving 
animals.
Moreover, our observation that phage-treated non-infected animals displayed some increase 
in IL1-production raises some concern about the use of phage therapy without a diagnosis or 
high suspicion of VAP. This phenomenon has also been observed in other studies, using other 
experimental settings and different phages (32), which highlights the need for a thorough 
reassessment of the exact impact of induced inflammation upon the clinical course of the 
disease. One obligatory step would be the use of highly purified, toxin free phage preparations 
produced using Good Manufacturing Practices (GMP).
Although phage therapy resulted in a reduction of bacterial densities within the lungs, it neither 
cleared nor cured the infection. This partial microbiological response might be due to either 
limited time of treatment or emergence of bacterial immunity against phages. We did not 
observe the emergence of resistance during short course therapy in vivo, which supports our 
previous observations using an anti-Pseudomonas phage cocktail for the treatment of 
endocarditis (26). In the absence of resistance, survival of bacteria following phage treatment 
may be attributable to a subpopulation of phage-tolerant persister cells; a hypothesis that we 
are currently investigating. Equally concerning, is the observation that the standard-of-care 
antibiotic chosen did not eliminate bacteria from the lung of infected animals. This supports 
claims that glycopeptides, may not be the best antibiotic choice in this infection setting, and 
that others, such as linezolid, which showed clear synergism with phages in vitro (Fig. E2), 
should be considered (33).
In a previous study, Yilmaz and colleagues reported synergy between teicoplanin and phages 
for the treatment of MRSA biofilms in an experimental implant-related infection model in rats 
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(34). In the current report, we did not observe improved outcomes for rats treated with a 
combination of anti-S. aureus phages and teicoplanin for the treatment of pneumonia. This 
correlates with research from others focusing on pneumonia due to K. pneumoniae (27), 
suggesting that synergism between phage and antibiotics is perhaps infection setting 
dependent. 
In addition, we found that mortality correlated not only with bacterial density within the lung 
(Fig. 2A), but also with lung tissue necrosis (Fig. E3). It is apparent that phage administration 
did not prevent or limit tissue necrosis or limit exotoxin production (Fig. E4), raising the question 
as to whether treatment outcomes could be further improved using adjunctive anti-toxin 
strategies such as protein synthesis inhibitors or anti-alpha toxin immunotherapeutics.  
Our study has some limitations. First, we used a rapidly lethal model of pneumonia, whereas 
the overall mortality of ventilator associated pneumonia in humans is much lower at around 10 
– 17% (35). As such, we plan to evaluate phage therapy in the future in less acute models of 
pneumonia, settings where longer courses of treatment are possible, which will likely provide 
further insights into phage pharmacodynamics and the development of bacterial phage 
immunity in vivo. 
Second, despite what we perceived to be good bioavailability of phages in the lung, we could 
not eradicate the infection. It is not yet clear how often phages should be given. We 
administered them once daily, since we expected phage amplification at the site of infection to 
be enough to decrease bacterial load. It is possible that we did not reach the optimal multiplicity 
of infection (MOI) appropriate to combat the high bacterial burden within the lungs. Further 
experiments are needed to evaluate the potential benefit of more frequent phage delivery 
and/or the application of more highly concentrated phage cocktails. 
In addition to more frequent application of phages, the route of administration could be 
optimised. For instance, aerosolisation could be used to deliver more phages to densely 
infected lung tissues. Aerosols are currently being used in mechanically ventilated patients to 
treat pneumonia (36) and previous studies succeeded in delivering anti-Pseudomonas phages 
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to the lung (28). Currently, no such report exists for anti-S. aureus phages. Moreover, the 
encapsulation of anti-Gram negative bacteriophages in phospholipid vesicles (37) and 
polymeric microparticles (28) effectively concentrated phages in the lung and these processes 
should be evaluated for anti-S. aureus phages. 
A well-known limitation of phage therapy is its narrow spectrum of activity (38). This caveat 
has clearly been demonstrated in the PhagoBurn study, where patients harbouring a resistant 
strain at the beginning of the treatment could not be cured from the wound infection. In the 
case of VAP, which often begins with prior colonisation (39), we may have the benefit of a time 
window of opportunity to personalize the phage treatment for the patients strain prior to the 
initiation of therapy.
Conclusions
Phage therapy significantly improved outcome compared to placebo and was equivalent to 
antibiotic in controlling MRSA-ventilator associated pneumonia. This study was the first to 
explore phage therapy for the treatment of MRSA experimental VAP. However, many 
questions remain unanswered, which preclude its immediate clinical implementation. Further 
studies are needed to assess whether alternative administration approaches, such as phage 
aerosolisation or other antibiotic-phage combinations (ie. using protein synthesis inhibitors as 
opposed to cell wall inhibitors), could further improve the efficacy of this therapy. 
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FIGURES
Figure 1. Survival of rats with MRSA VAP treated with phage, antibiotics or a 
combination of both. Study design of the VAP model with sampling time points (A). Kaplan-
Meier survival curves for animals with MRSA VAP that were untreated (n= 10), treated with 
the phage cocktail (n= 12), treated with the conventional antibiotic, teicoplanin, (n= 12) or a 
combination of both (n= 11) (B).
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Figure 2. Bacterial and phage loads in the lung and spleen of animals with experimental 
MRSA VAP. Animals were divided into two groups based on mortality: non-survivors and 
survivors. Bacterial burden for the lungs of rats infected with MRSA. Significance was 
determined using t test, **** p < 0.0001 (A). Comparative analysis of lung bacterial load for 
rats treated with phages, teicoplanin, or a combination of both (B). Bacterial burden for the 
spleen of rats infected with MRSA (C). Phage titres for the lung and spleen (D). Comparative 
analysis of phage burden for the lung of non-surviving and surviving rats. The p-value was 
determined using t test (E). Correlation analysis between lung phage titres and bacterial loads. 
Pearson 2-tailed correlation test, r = 0.33, p = 0.12. Line of best fit represented in black (F). 
For each panel, data are summarised using the mean (solid black lines), and the limit of 
detection for each organ is represented by dotted black lines. Abbreviations: CFU, colony 
forming units; PFU, plaque forming units; Teico, Teicoplanin. 
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Figure 3. Determination of phage susceptibilities for bacteria isolated from the lungs of 
phage treated rats. One hundred bacterial colonies were tested for phage resistance using 
cross streak assays. All isolates were susceptible to the phage based on the absence of growth 
in the phage streak. Four representative colonies are shown. 
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Figure 4. Histopathogical scoring of lung tissue following MRSA VAP. Rat lung inoculated 
with MRSA (untreated control) showing a necrotic bronchiolus (arrows) with intraluminal 
bacterial colonies (*), which invade surrounding, necrotic alveoli (A). Scoring for lung 
histopathology was published by Montgomery et al(23). A score of 1, 2, 3 represents mild, 
moderate or severe pneumonia, respectively. Significant differences were determined using 
one-way ANOVA with multiple comparisons using the method of Tukey. *** p < 0.0005, **** p 
< 0.0001 (B). Lung 96 hours after MRSA inoculation followed by phage therapy displaying a 
hyperplastic bronchiolus (regeneration, arrow) filled with and surrounded by many 
inflammatory cells (neutrophilic granulocytes, macrophages) that display a good immune 
response and few bacterial micro-colonies (*) (C). Comparative analysis of non-surviving and 
surviving animals following treatment. Significant differences were determined using two-way 
ANOVA with multiple comparisons using the method of Holm and Sidak. As none of the 
untreated animals survived, the MRSA group was excluded from the two-way ANOVA. * p < 
0.05, ** p < 0.01. (D). A and C are representative images of 200x HPF (high power field) 
magnification. For B and D, animals that died are represented by crosses, and those that 
survived are represented by closed circles. Black lines represent the mean. 
Page 18 of 35 AJRCCM Articles in Press. Published on 01-July-2019 as 10.1164/rccm.201812-2372OC 
 Copyright © 2019 by the American Thoracic Society 
Figure 5. Evaluation of inflammatory biomarkers for rats with experimental MRSA VAP. 
Concentration of select cytokines in the blood of rats following two hours of MRSA pneumonia 
(black bars, n=25) compared to uninfected controls (SHAM, white bars, n=12). Significant 
differences were determined using two-way ANOVA with multiple comparisons using the 
method of Holm and Sidak, ** p < 0.01. # indicates that levels were below the limit of detection 
(A). Cytokine concentration dynamics in the blood of late death/surviving rats following MRSA 
VAP (t0) and treatment with phages (n=7) or teicoplanin (n=6) or combination of both (n=5), as 
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well as uninfected controls (SHAM, n=5), and uninfected controls treated with phages 
(SHAM+phage, n=7) (B). For each panel, data represent the mean and standard error. 
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MATERIAL AND METHODS
Bacteria and Phages 
Bacterial strain and growth conditions. MRSA strain AW7 was isolated from a patient with 
bacteremia (1-3). The strain is representative of sequence type 247 as determined by whole-
genome sequencing (CC8, SCCmecI [1B], hlgABC+, lukDE+, sea+, scn+, PVL-). Importantly, 
AW7 produces α-hemolysin, which is a critical mediator of S. aureus pneumonia (4-6). In 
addition to beta lactam resistance, the genome harbors resistance determinants for 
aminoglycosides, tetracyclines, macrolides and chloramphenicol. AW7 was stored frozen in 
Tryptic Soy Broth (TSB) containing 10% (v/v) glycerol at -80oC and sub-cultured on Tryptic 
Soy Agar (TSA) plates to ensure purity before testing. For liquid culture, TSB was inoculated 
with at least five single colonies and incubated for 24 hours with agitation (200 rpm) at 37oC. 
Bacteriophages. Phages K and 3A were purchased from the University of Laval, Québec 
(https://www.phage.ulaval.ca/en/phages-catalog/). Phage 2003 was isolated from the 
staphylococcal phage product of the Eliava Institute of Bacteriophages, Microbiology and 
Virology, Tbilissi, Georgia. Briefly, serial dilutions of the phage product were mixed with 
S. aureus strain 8325-4 and grown in double-layer TSA plates. A single plaque was excised, 
resuspended in 2 mL of sterile saline, and then passed through a 0.45 µm syringe filter. The 
method was repeated three times to ensure isolation of a single phage. Phage 2002 was 
isolated from sewage water (Vidy wastewater treatment plants, Lausanne, Switzerland). 
Briefly, a sample of wastewater was added to a mixture of five different S. aureus strains 
(S144-1, S47-1, Bk, G04 and Jn) in liquid culture then plated in double-layer TSA plates. A 
single plaque was excised and the phage was purified as described above for Phage 2003. 
To produce large quantities of phage, amplification was performed in double-layer agar 
plates using S. aureus strain 8325-4 as a susceptible host. For each agar plate, the soft layer 
containing phages was scraped and suspended in 10 ml of sterile saline, homogenized by 
vortex then centrifuged at 4000 rpm for 40 minutes. The supernatant containing phages was 
then passed through a 0.45 µm filter. The concentration of the phage preparation was 
determined using double-layer assays. The host-range of each phage from the cocktail was 
determined in double layer-assays for 83 diverse S. aureus isolates.
Assessment of phage resistance development. S. aureus AW7 was infected with each of 
the four phages independently, as well as with a multiphage cocktail at a multiplicity of 
infection (MOI) of 0.1 in 96-well plates. Plates were incubated at 37°C for 24h. Optical 
density (OD595) was recorded every ten minutes. 
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Checkerboard assay. Phage-antibiotic synergy was determined using checkerboard 
assays. Briefly, two-fold dilutions of teicoplanin beginning at 32 µg/ml, and ten-fold dilutions 
of the phage cocktail starting at a concentration of ~2x107 PFU/ml were prepared in sterile 
TSB. Decreasing concentrations of teicoplanin (50 µl volumes) were distributed along 
columns of a 96 well plate, and decreasing concentrations of phage (also 50 µl volumes) 
were distributed along rows. A suspension of S. aureus AW7 (~1x106 CFU/ml) was prepared 
in sterile TSB, and 100 µl was distributed into each well (total volume 200 µl in each well, 
final inoculum 5x105 CFU/ml). Each well from one column served as a growth control (no 
antibiotic or phage), and a second column was not inoculated with bacteria (no growth 
control). The lowest concentration of phage, antibiotic and the combination of both to inhibit 
bacterial growth was determined by assessing turbidity with an unaided eye, as defined by 
European Committee on Antimicrobial Susceptibility Testing guidelines.
Rabbit red blood cell lysis assay.  S. aureus AW7 was grown to mid-exponential phase, at 
which point cells were treated with sub inhibitory concentrations (1/4 of the MIC) of antibiotics 
and phages alone or in combination for 6 hours (teicoplanin 0.125 ug/ml, linezolid 0.25 ug/ml, 
phages at an MOI of 0.001). Cultures were centrifuged and supernatants were filter 
sterilized. Rabbit red blood cell lysis experiments using filtered supernatants were then 
performed as described previously (7). Four biological replicates were performed for each 
experimental condition. Linezolid reduces exotoxin production in S. aureus and was included 
as a control. 
Experimental model of ventilator associated pneumonia in rats (additional 
information)
Power calculation. In order to perform a power calculation, we hypothesized that treatment 
with phages and standard antibiotic therapy would increase survival from 20% to 80% within 
4 days (primary outcome). These estimates, with an alpha=0.05 and a power (1-β) = 0.8 
required a sample size of 13 per group (Power analysis performed with SigmaPlot 12.0, 
module “Sample Size for Proportion”). Not all of the animals were fit enough to be 
randomized following surgery as determined by the Cantonal Committee on Animal 
Experiments of the State of Bern (approval BE 83/17), thus the sample sizes for each group 
were 10-12 animals.
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Blinding Procedure. Treatment syringes (phages, antibiotic or a combination of both) as 
well as placebo control syringes (0.9% NaCl) were prepared and four doses were packaged 
into unmarked envelopes. Envelopes were randomly delivered to the surgeon prior to the 
initiation of therapy by an independent researcher who did not participate further in the study. 
Criteria for Euthanasia. Animal welfare was determined at least three times per day using 
an in-house Welfare Score Sheet for Rodents, which is summarised in Table 1. Animals 
were excluded from randomisation if they showed persistent respiratory instability, missing 
reflexes as measured by a failure to withdraw from painful stimulus, or an inability to remain 
upright two hours after anesthesia. Animals were euthanized if the total score was greater 
than ‘1’ or if body weight decreased by more than 20%. 
Table 1. Welfare Score Sheet for Rodents 
Secondary outcomes
Bacterial and phage loads in tissues and blood. Bacterial loads were determined from 
heparinized blood and organs. Organs were first mechanically homogenized in weight-
adapted volumes of 0.9% NaCl (2 ml for spleens, 3 ml for lungs). Samples were serially 
diluted and plated onto TSA. Plates were incubated at 37°C and colonies were counted the 
following day. Phage loads were determined using double-layer agar plates, whereby the top 
agar layer consisted of 100 µl of diluted sample and 3.0 x 107 CFU of MRSA AW7. Plates 
were incubated at 37°C and plaques were counted the following day.
Histopathology and histopathological grading. Cranial and caudal tissue samples of the 
right and left lung from each rat were fixed in 10% neutral buffered formalin for 24 hours and 
embedded in paraffin. Blocks were sectioned and slides were stained with hematoxylin and 
eosin (H&E). On H&E-stained sections, morphologic changes were recorded as previously 
Observation Details Score
Attitude BAR (bright/active/responsive) 0.0
 Burrowing or hiding, quiet but rouses when touched 0.1
 Markedly diminished exploratory activity when assessed for neurobehavioral score, vocalizes or aggressive when touched 0.4
Porphyrins None 0.0
Mild around eyes and/or nostrils 0.1
 Obvious on face and/or paws 0.4
Gait and Posture Normal 0.0
Mild incoordination when stimulated, hunched posture, mild piloerection 0.1
 Obvious ataxia or head tilt, hunching, drags one or both limbs, severe piloerection 0.4
Weight Weight gain or weight loss < 5% 0.0
 Weight loss 5 – 10 % 0.1
 Weight loss > 10 % 0.4
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described Montgomery et al(8). Microscopic evaluation was performed in a blinded fashion 
without knowledge of treatment group by a European board certified veterinary pathologist 
(CG).
Inflammatory Cytokine Analysis. Heparinized blood was centrifuged at 2,000 g for 5 
minutes, and the plasma was frozen at –80°C for future analysis. Plasma concentrations of 
inflammation biomarkers interleukin (IL)–6, IL-1α, IL-1β, IL-10, IL-17A, IL-18 and tumor 
necrosis factor (TNF)–α were determined by microsphere-based multiplex immunoassay 
(BioRad, BioPlex pro Luminex Assay USA) on the Luminex platform according to the 
recommendations of the manufacturer.
Phage resistance assays. Phage cross streak assays were performed to assess phage 
resistance as described previously by Duerkop et al.(9). Briefly, 50 µl of the phage cocktail 
was streaked in a straight line across the surface of a TSA plate. Single colonies harvested 
from lung tissue homogenates were resuspended in 20 µl of sterile PBS then 5µl of the 
suspension was streaked across the plate intersecting the phage in a perpendicular 
arrangement. Plates were incubated overnight at 37°C and susceptibility was determined by 
the absence of bacterial growth within the phage streak. Five colonies from each of ten lungs 
(n=50) from animals treated with phage, and the same from animals treated with a 
combination of phage and antibiotics were tested.
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Figure E1. Characterization of the anti-Staphylococcus aureus phages used in this 
study. Host-range determination for each phage against 83 staphylococcal isolates from 
diverse sources (A). In vitro assessment of phage resistance development. S. aureus AW7 
was infected with each of the four phages independently, as well as with a multiphage 
cocktail at a multiplicity of infection (MOI) of 0.1. Optical density (OD595) was recorded every 
ten minutes. Data are presented as the mean (line) ± SEM (fill) from 4-5 replicates (B).
B
A
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Figure E2. Determination of phage-antibiotic synergism/antagonism for 
Staphylococcus aureus strain AW7. The minimum inhibitory concentration (MIC) for 
teicoplanin was 0.5 μg/mL (red box) and the minimal inhibitory multiplicity of infection 
(MIMOI) for the phage cocktail was 0.01 (blue box). No synergy between phages and 
teicoplanin was observed (A).  The MIC for Linezolid was 1.0 μg/mL (orange box). The 
combination of phages at an MOI of 0.0001 and linezolid at 0.25X the MIC inhibited growth 
(yellow box), indicating synergism (B). +, growth control; -, uninoculated control; MOI, 
multiplicity of infection. 
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Figure E3. Necrosis scoring of lung tissue following MRSA VAP. Necrosis of lung tissue 
was scored as follows: 0, no necrosis; 1, mild necrosis (1-9%); 2, moderate necrosis (10-
50% of the sample); 3, severe necrosis (>50% of the sample) (A). Comparison of Necrosis 
scores for the lungs of animals treated with phages, teicoplanin or a combination of both (B). 
Bars represent the mean. 
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Figure E4. Functional assessment of exotoxin activity as inferred from rabbit red 
blood cell lysis. Cultures of S. aureus AW7 were exposed to sub inhibitory concentrations 
of antibiotics and/or phages for six hours. Serial dilutions of filtered supernatants were then 
added to rabbit red blood cells at various dilutions and lysis was monitored by assessing 
optical density (550nm). Linezolid, which reduces exotoxin production in S. aureus, was 
included as a control. Data are represented by the mean and standard error of four biological 
replicates.  
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